{
  "description": "Gold standard dataset for SNP/indel variants - curated with 2024 FDA approvals",
  "version": "2.1-snp-2024-corrected",
  "last_updated": "2024-12",
  "entries": [
    {
      "gene": "BRAF",
      "variant": "V600E",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: dabrafenib+trametinib, vemurafenib+cobimetinib, encorafenib+binimetinib",
      "references": [
        "FDA approval 2013 (vemurafenib), 2014 (dabrafenib+trametinib)",
        "Long GV et al. N Engl J Med 2014"
      ]
    },
    {
      "gene": "BRAF",
      "variant": "V600E",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: dabrafenib+trametinib for BRAF V600E NSCLC (2017)",
      "references": [
        "FDA approval June 2017",
        "Planchard D et al. Lancet Oncol 2016"
      ]
    },
    {
      "gene": "BRAF",
      "variant": "V600E",
      "tumor_type": "Anaplastic Thyroid Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: dabrafenib+trametinib for BRAF V600E ATC (2018)",
      "references": [
        "FDA approval May 2018",
        "Subbiah V et al. J Clin Oncol 2018"
      ]
    },
    {
      "gene": "BRAF",
      "variant": "V600E",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier I",
      "notes": "CORRECTED FROM TIER II. FDA-approved: encorafenib+cetuximab for BRAF V600E mCRC (2020). Even though later-line, BRAF V600E IS the biomarker indication for this therapy.",
      "references": [
        "FDA approval April 2020",
        "Kopetz S et al. N Engl J Med 2019 (BEACON trial)"
      ]
    },
    {
      "gene": "BRAF",
      "variant": "V600K",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: same BRAF inhibitors as V600E, included in label",
      "references": [
        "FDA label includes V600E and V600K",
        "Long GV et al. Lancet 2015"
      ]
    },
    {
      "gene": "BRAF",
      "variant": "G469A",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier III",
      "notes": "Non-V600 BRAF mutation. Not FDA-approved, variable response to BRAF inhibitors, limited data",
      "references": [
        "Dahlman KB et al. Cancer Discov 2012",
        "Yao Z et al. Cancer Cell 2017"
      ]
    },
    {
      "gene": "EGFR",
      "variant": "L858R",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: osimertinib (preferred), erlotinib, gefitinib, afatinib",
      "references": [
        "FDA approvals 2004-2018",
        "Soria JC et al. N Engl J Med 2018 (FLAURA)"
      ]
    },
    {
      "gene": "EGFR",
      "variant": "T790M",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: osimertinib for T790M+ NSCLC after progression on 1st/2nd-gen TKI. T790M IS the indication for osimertinib.",
      "references": [
        "FDA approval November 2015",
        "Mok TS et al. N Engl J Med 2017 (AURA3)"
      ]
    },
    {
      "gene": "EGFR",
      "variant": "C797S",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier II",
      "notes": "Resistance marker to osimertinib. Guides treatment selection (may use 1st-gen TKIs if in trans with T790M). No FDA-approved C797S-specific therapy.",
      "references": [
        "Thress KS et al. Nat Med 2015",
        "NCCN Guidelines - resistance marker"
      ]
    },
    {
      "gene": "EGFR",
      "variant": "G719S",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: afatinib for uncommon EGFR mutations including G719X (2018 label expansion)",
      "references": [
        "FDA label expansion 2018",
        "Yang JC et al. Lancet Oncol 2015"
      ]
    },
    {
      "gene": "KRAS",
      "variant": "G12C",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: sotorasib (2021), adagrasib (2022)",
      "references": [
        "FDA approval May 2021 (sotorasib), Dec 2022 (adagrasib)",
        "Skoulidis F et al. N Engl J Med 2021"
      ]
    },
    {
      "gene": "KRAS",
      "variant": "G12C",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: adagrasib+cetuximab for KRAS G12C mCRC (2024)",
      "references": [
        "FDA approval March 2024",
        "Yaeger R et al. N Engl J Med 2023 (KRYSTAL-1)"
      ]
    },
    {
      "gene": "KRAS",
      "variant": "G12D",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier II",
      "notes": "CORRECTED FROM TIER I. Resistance marker: predicts resistance to anti-EGFR therapy (cetuximab, panitumumab). Guideline-mandated testing. By strict AMP/ASCO/CAP, exclusionary biomarkers without FDA-approved targeted therapy are Tier II, not Tier I.",
      "references": [
        "Allegra CJ et al. J Clin Oncol 2009",
        "NCCN Guidelines - required testing before anti-EGFR"
      ]
    },
    {
      "gene": "KRAS",
      "variant": "G12D",
      "tumor_type": "Pancreatic Cancer",
      "expected_tier": "Tier III",
      "notes": "No FDA-approved targeted therapy. KRAS G12D inhibitors in early trials only.",
      "references": [
        "Hallin J et al. Cancer Discov 2022 (preclinical)",
        "Clinical trials ongoing (MRTX1133)"
      ]
    },
    {
      "gene": "KRAS",
      "variant": "G13D",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier II",
      "notes": "CORRECTED FROM TIER I. Resistance marker: predicts resistance to anti-EGFR therapy. Same reasoning as G12D - guideline-mandated but exclusionary only, no FDA-approved targeted therapy FOR KRAS.",
      "references": [
        "De Roock W et al. JAMA 2010",
        "NCCN Guidelines"
      ]
    },
    {
      "gene": "NRAS",
      "variant": "Q61K",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier II",
      "notes": "Resistance marker: predicts resistance to anti-EGFR therapy. Required testing per NCCN. Same tier as KRAS mutations in CRC.",
      "references": [
        "Douillard JY et al. N Engl J Med 2013",
        "NCCN Guidelines"
      ]
    },
    {
      "gene": "NRAS",
      "variant": "Q61K",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier III",
      "notes": "CORRECTED FROM TIER II. No FDA-approved NRAS-targeted therapy. MEK inhibitors (binimetinib) show activity in NEMO trial but NOT FDA-approved as monotherapy for NRAS-mutant melanoma. Investigational only.",
      "references": [
        "Dummer R et al. Lancet Oncol 2017 (NEMO)",
        "No FDA approval for NRAS-targeted therapy in melanoma"
      ]
    },
    {
      "gene": "NRAS",
      "variant": "G12D",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier III",
      "notes": "CORRECTED FROM TIER II. No FDA-approved therapy. Limited clinical data compared to Q61 mutations. Investigational only.",
      "references": [
        "Johnson DB et al. Cancer 2015",
        "Preclinical MEK inhibitor sensitivity"
      ]
    },
    {
      "gene": "PIK3CA",
      "variant": "H1047R",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: alpelisib + fulvestrant for PIK3CA-mutated HR+/HER2- breast cancer (2019). PIK3CA mutation IS the companion diagnostic.",
      "references": [
        "FDA approval May 2019",
        "André F et al. N Engl J Med 2019 (SOLAR-1)"
      ]
    },
    {
      "gene": "PIK3CA",
      "variant": "E545K",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: alpelisib label includes E545K as actionable PIK3CA mutation",
      "references": [
        "FDA-approved companion diagnostic includes E545K",
        "André F et al. N Engl J Med 2019"
      ]
    },
    {
      "gene": "PIK3CA",
      "variant": "E542K",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: alpelisib label includes E542K as actionable PIK3CA mutation",
      "references": [
        "FDA-approved companion diagnostic includes E542K",
        "André F et al. N Engl J Med 2019"
      ]
    },
    {
      "gene": "PIK3CA",
      "variant": "H1047R",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier III",
      "notes": "No FDA-approved PI3K inhibitor in CRC. Alpelisib approved only in breast cancer.",
      "references": [
        "Rodon J et al. Nat Rev Clin Oncol 2013",
        "No positive Phase 3 in CRC"
      ]
    },
    {
      "gene": "IDH1",
      "variant": "R132H",
      "tumor_type": "Acute Myeloid Leukemia",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: ivosidenib for IDH1-mutated AML (2018)",
      "references": [
        "FDA approval July 2018",
        "DiNardo CD et al. N Engl J Med 2018"
      ]
    },
    {
      "gene": "IDH1",
      "variant": "R132C",
      "tumor_type": "Cholangiocarcinoma",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: ivosidenib for IDH1-mutated cholangiocarcinoma (2021)",
      "references": [
        "FDA approval August 2021",
        "Abou-Alfa GK et al. Lancet Oncol 2020 (ClarIDHy)"
      ]
    },
    {
      "gene": "IDH2",
      "variant": "R140Q",
      "tumor_type": "Acute Myeloid Leukemia",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: enasidenib for IDH2-mutated AML (2017)",
      "references": [
        "FDA approval August 2017",
        "Stein EM et al. Blood 2017"
      ]
    },
    {
      "gene": "KIT",
      "variant": "D816V",
      "tumor_type": "Systemic Mastocytosis",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: avapritinib for advanced SM with D816V (2021), midostaurin (2017)",
      "references": [
        "FDA approval June 2021 (avapritinib)",
        "DeAngelo DJ et al. N Engl J Med 2021 (PATHFINDER)"
      ]
    },
    {
      "gene": "KIT",
      "variant": "D816H",
      "tumor_type": "Systemic Mastocytosis",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: avapritinib label covers D816 mutations broadly",
      "references": [
        "FDA label includes D816 mutations",
        "Gotlib J et al. Blood 2021"
      ]
    },
    {
      "gene": "KIT",
      "variant": "V560D",
      "tumor_type": "Gastrointestinal Stromal Tumor",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: imatinib for KIT-mutated GIST. Exon 9 mutations (including V560D) are imatinib-sensitive, first-line therapy.",
      "references": [
        "FDA approval 2002",
        "Demetri GD et al. N Engl J Med 2002"
      ]
    },
    {
      "gene": "KIT",
      "variant": "D816V",
      "tumor_type": "Gastrointestinal Stromal Tumor",
      "expected_tier": "Tier II",
      "notes": "Imatinib-resistant. Avapritinib shows activity but FDA-approved for PDGFRA D842V GIST, not specifically for KIT D816V in GIST. Very rare in GIST (<1%).",
      "references": [
        "Heinrich MC et al. J Clin Oncol 2008",
        "Avapritinib shows activity in D816V GIST"
      ]
    },
    {
      "gene": "ESR1",
      "variant": "Y537S",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier I",
      "notes": "Resistance marker: confers resistance to aromatase inhibitors. FDA-approved: elacestrant for ESR1-mutated ER+ breast cancer (2023)",
      "references": [
        "FDA approval January 2023",
        "Bidard FC et al. J Clin Oncol 2022 (EMERALD)"
      ]
    },
    {
      "gene": "ESR1",
      "variant": "D538G",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier I",
      "notes": "Resistance marker: confers AI resistance. Elacestrant FDA-approved for ESR1-mutated disease.",
      "references": [
        "FDA approval January 2023",
        "Chandarlapaty S et al. JAMA Oncol 2016"
      ]
    },
    {
      "gene": "TP53",
      "variant": "R175H",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier III",
      "notes": "Prognostic but not predictive. No FDA-approved TP53-targeted therapy. Poor prognosis marker.",
      "references": [
        "Olivier M et al. Hum Mutat 2010",
        "Prognostic, not therapeutically actionable"
      ]
    },
    {
      "gene": "TP53",
      "variant": "R273H",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier III",
      "notes": "Prognostic but not predictive. No FDA-approved TP53-targeted therapy.",
      "references": [
        "IARC TP53 Database",
        "Prognostic significance only"
      ]
    },
    {
      "gene": "APC",
      "variant": "R1450*",
      "tumor_type": "Colorectal Cancer",
      "expected_tier": "Tier III",
      "notes": "Diagnostic/prognostic for CRC but not predictive for therapy selection.",
      "references": [
        "Fearon ER et al. Cell 1990",
        "Not predictive for therapy"
      ]
    },
    {
      "gene": "VHL",
      "variant": "R167Q",
      "tumor_type": "Clear Cell Renal Cell Carcinoma",
      "expected_tier": "Tier III",
      "notes": "VHL loss is diagnostic for ccRCC but VHL mutation status does not predict response to approved therapies (TKIs, IO). Not actionable.",
      "references": [
        "Choueiri TK et al. Eur Urol 2021",
        "Mutation status not predictive"
      ]
    },
    {
      "gene": "FGFR3",
      "variant": "S249C",
      "tumor_type": "Bladder Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: erdafitinib for FGFR3-mutated urothelial carcinoma (2019)",
      "references": [
        "FDA approval April 2019",
        "Loriot Y et al. N Engl J Med 2019"
      ]
    },
    {
      "gene": "FGFR2",
      "variant": "N549K",
      "tumor_type": "Cholangiocarcinoma",
      "expected_tier": "Tier II",
      "notes": "FGFR2 fusions/rearrangements have FDA-approved therapies (pemigatinib, infigratinib, futibatinib). N549K is a point mutation - less clear if it falls under FDA approval language which emphasizes fusions. Tier II for point mutations unless evidence shows equivalence to fusions.",
      "references": [
        "FDA approvals 2020-2022",
        "Abou-Alfa GK et al. Lancet Oncol 2020 (FIGHT-202)"
      ]
    },
    {
      "gene": "MET",
      "variant": "D1228N",
      "tumor_type": "Non-Small Cell Lung Cancer",
      "expected_tier": "Tier II",
      "notes": "MET exon 14 skipping mutations have FDA-approved therapies (capmatinib, tepotinib). D1228N can cause exon 14 skipping. If confirmed to cause skipping, may be Tier I. As point mutation alone without confirmed functional effect, Tier II.",
      "references": [
        "Recondo G et al. Cancer Discov 2020",
        "Guides MET inhibitor selection"
      ]
    },
    {
      "gene": "RET",
      "variant": "M918T",
      "tumor_type": "Medullary Thyroid Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: selpercatinib, pralsetinib for RET-mutated MTC",
      "references": [
        "FDA approval May 2020 (selpercatinib)",
        "Wirth LJ et al. N Engl J Med 2020"
      ]
    },
    {
      "gene": "BRCA2",
      "variant": "E1493*",
      "tumor_type": "Ovarian Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: olaparib, rucaparib, niraparib for BRCA-mutated ovarian cancer",
      "references": [
        "FDA approvals 2014-2018",
        "Moore K et al. N Engl J Med 2018 (SOLO1)"
      ]
    },
    {
      "gene": "BRCA1",
      "variant": "C61G",
      "tumor_type": "Breast Cancer",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: olaparib, talazoparib for germline BRCA-mutated HER2- breast cancer. C61G is a known pathogenic BRCA1 variant.",
      "references": [
        "FDA approval January 2018 (olaparib)",
        "Robson M et al. N Engl J Med 2017 (OlympiAD)"
      ]
    },
    {
      "gene": "PDGFRA",
      "variant": "D842V",
      "tumor_type": "Gastrointestinal Stromal Tumor",
      "expected_tier": "Tier I",
      "notes": "FDA-approved: avapritinib for PDGFRA D842V GIST (2020). Imatinib-resistant.",
      "references": [
        "FDA approval January 2020",
        "Heinrich MC et al. Lancet Oncol 2020 (NAVIGATOR)"
      ]
    },
    {
      "gene": "POLE",
      "variant": "P286R",
      "tumor_type": "Endometrial Cancer",
      "expected_tier": "Tier II",
      "notes": "Ultramutated phenotype, favorable prognosis. May predict immunotherapy response. Not FDA-approved indication but clinical utility.",
      "references": [
        "Church DN et al. J Clin Oncol 2015",
        "Prognostic, potential IO predictor"
      ]
    },
    {
      "gene": "SMAD4",
      "variant": "R361H",
      "tumor_type": "Pancreatic Cancer",
      "expected_tier": "Tier III",
      "notes": "Prognostic only. Associated with worse outcomes, metastatic pattern. No targeted therapy.",
      "references": [
        "Iacobuzio-Donahue CA et al. J Clin Invest 2009",
        "Not therapeutically actionable"
      ]
    },
    {
      "gene": "CDKN2A",
      "variant": "R80*",
      "tumor_type": "Melanoma",
      "expected_tier": "Tier III",
      "notes": "Prognostic/diagnostic. Associated with CDK4/6 inhibitor sensitivity in some contexts but not FDA-approved indication in melanoma.",
      "references": [
        "Genomic classification of cutaneous melanoma. Cell 2015",
        "Not validated predictive biomarker"
      ]
    },
    {
      "gene": "ARID1A",
      "variant": "Q1334*",
      "tumor_type": "Ovarian Cancer",
      "expected_tier": "Tier III",
      "notes": "Potential synthetic lethality with ATR/PARP inhibitors. Phase 2 data only, not FDA-approved.",
      "references": [
        "Bitler BG et al. Nat Med 2015",
        "Preclinical rationale, trials ongoing"
      ]
    }
  ]
}